---
title: "Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285999146.md"
description: "Charles River Laboratories International Inc. (CRL) shares fell 5.16% to $168.46 on Monday, marking the fourth consecutive day of losses. This decline occurred despite a positive trading session for the overall market, with the S&P 500 and Dow Jones both rising 0.19%. CRL's stock is now 26.40% below its 52-week high of $228.88. In comparison, competitors Labcorp Holdings Inc. and Alnylam Pharmaceuticals Inc. had mixed performances, while trading volume for CRL was below its 50-day average."
datetime: "2026-05-11T21:18:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285999146.md)
  - [en](https://longbridge.com/en/news/285999146.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285999146.md)
---

# Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Charles River Laboratories International Inc. (CRL) slipped 5.16% to $168.46 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.19% to 7,412.84 and the Dow Jones Industrial Average rising 0.19% to 49,704.47.

This was the stock's fourth consecutive day of losses.

Charles River Laboratories International Inc. closed 26.40% below its 52-week high of $228.88, which the company achieved on January 13th.

The stock underperformed when compared to some of its competitors Monday, as Labcorp Holdings Inc. (LH) rose 0.38% to $255.08, Alnylam Pharmaceuticals Inc. (ALNY) fell 3.46% to $284.84, and Bio-Techne Corp. (TECH) fell 1.94% to $47.42.

Trading volume (762,239) remained 110,869 below its 50-day average volume of 873,108.

Data source: Dow Jones Market Data, FactSet. Data compiled May 11, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-11-26 1718ET

### Related Stocks

- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [LH.US](https://longbridge.com/en/quote/LH.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)

## Related News & Research

- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)
- [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)